Suppression of wheal and flare in histamine test by the main H1 antihistamines commercialized in Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1590/abd1806-4841.20186807 http://hdl.handle.net/11449/176257 |
Resumo: | Background: Several dermatoses are mediated by histamine, such as urticaria, angioedema, and papular urticaria. There are no Brazilian studies comparing the potency of antihistamines. Objectives: To evaluate the tolerability and efficacy of the main commercial brand and generic H1 antihistamines, regarding the suppression of the wheal and flare to the histamine test. Methods: A quasi-experimental, open study with 10 healthy adults submitted to the histamine test on the ventral aspect of the forearms. After 20 minutes, wheal and flares were measured. The tests were performed after two hours of intake of dexchlorpheniramine, hydroxyzine, levocetirizine, fexofenadine, cetirizine, loratadine, ebastine, desloratadine, epinastine and rupatadine, as well as generics of loratadine, cetirizine and fexofenadine. Results: All antihistamines presented a reduction in the wheal compared to the control (p <0.02), as well as in the flare, except for rupatadine (p = 0.70). In the internal comparison, cetirizine, fexofenadine, epinastine, levocetirizine, dexchlorpheniramine and hydroxyzine were the most potent, with no difference between them (p > 0.1). As for halo, cetirizine, epinastine, hydroxyzine and fexofenadine were the most potent, with no difference between them (p > 0.1). The most common adverse effect was drowsiness, which was more prevalent among first-generation drugs (p < 0.01). Generic loratadine, fexofenadine and cetirizine halos were higher than their controls (p <0.03). Study limitations: A single-center study evaluating only aspects related to histamine. Conclusions: Brazilian commercial antihistamines presented different profiles of inhibition of wheal and flares in the histamine test, as well as adverse effects. Generic loratadine, fexofenadine and cetirizine presented larger flares than brand drugs. |
id |
UNSP_6d8254636d348053261b6c20ff3396a5 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/176257 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Suppression of wheal and flare in histamine test by the main H1 antihistamines commercialized in BrazilAngioedemaHistamine antagonistsHistamine H1 antagonistsHistamine H2 antagonistsUrticariaBackground: Several dermatoses are mediated by histamine, such as urticaria, angioedema, and papular urticaria. There are no Brazilian studies comparing the potency of antihistamines. Objectives: To evaluate the tolerability and efficacy of the main commercial brand and generic H1 antihistamines, regarding the suppression of the wheal and flare to the histamine test. Methods: A quasi-experimental, open study with 10 healthy adults submitted to the histamine test on the ventral aspect of the forearms. After 20 minutes, wheal and flares were measured. The tests were performed after two hours of intake of dexchlorpheniramine, hydroxyzine, levocetirizine, fexofenadine, cetirizine, loratadine, ebastine, desloratadine, epinastine and rupatadine, as well as generics of loratadine, cetirizine and fexofenadine. Results: All antihistamines presented a reduction in the wheal compared to the control (p <0.02), as well as in the flare, except for rupatadine (p = 0.70). In the internal comparison, cetirizine, fexofenadine, epinastine, levocetirizine, dexchlorpheniramine and hydroxyzine were the most potent, with no difference between them (p > 0.1). As for halo, cetirizine, epinastine, hydroxyzine and fexofenadine were the most potent, with no difference between them (p > 0.1). The most common adverse effect was drowsiness, which was more prevalent among first-generation drugs (p < 0.01). Generic loratadine, fexofenadine and cetirizine halos were higher than their controls (p <0.03). Study limitations: A single-center study evaluating only aspects related to histamine. Conclusions: Brazilian commercial antihistamines presented different profiles of inhibition of wheal and flares in the histamine test, as well as adverse effects. Generic loratadine, fexofenadine and cetirizine presented larger flares than brand drugs.Faculdade de Medicina de Botucatu Universidade Estadual Paulista “Júlio de Mesquita Filho” (FMB-Unesp)Department of Dermatology and Radiotherapy Faculdade de Medicina de Botucatu Universidade Estadual Paulista “Júlio de Mesquita Filho” (FMB-Unesp)Faculdade de Medicina de Botucatu Universidade Estadual Paulista “Júlio de Mesquita Filho” (FMB-Unesp)Department of Dermatology and Radiotherapy Faculdade de Medicina de Botucatu Universidade Estadual Paulista “Júlio de Mesquita Filho” (FMB-Unesp)Universidade Estadual Paulista (Unesp)Maciel-Guerra, Helena [UNESP]Jorge, Marília Formentini Scotton [UNESP]Carrijo, Ana Cláudia Nazareno dos Anjos [UNESP]Miot, Hélio Amante [UNESP]Penha, Mariana Álvares [UNESP]Libório, Ricardo da Silva [UNESP]Parise-Fortes, Maria Rita [UNESP]2018-12-11T17:19:49Z2018-12-11T17:19:49Z2018-03-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article233-237application/pdfhttp://dx.doi.org/10.1590/abd1806-4841.20186807Anais Brasileiros de Dermatologia, v. 93, n. 2, p. 233-237, 2018.1806-48410365-0596http://hdl.handle.net/11449/17625710.1590/abd1806-4841.20186807S0365-059620180002002332-s2.0-85046400733S0365-05962018000200233.pdfScopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengAnais Brasileiros de Dermatologia0,520info:eu-repo/semantics/openAccess2024-08-14T18:45:21Zoai:repositorio.unesp.br:11449/176257Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-14T18:45:21Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Suppression of wheal and flare in histamine test by the main H1 antihistamines commercialized in Brazil |
title |
Suppression of wheal and flare in histamine test by the main H1 antihistamines commercialized in Brazil |
spellingShingle |
Suppression of wheal and flare in histamine test by the main H1 antihistamines commercialized in Brazil Maciel-Guerra, Helena [UNESP] Angioedema Histamine antagonists Histamine H1 antagonists Histamine H2 antagonists Urticaria |
title_short |
Suppression of wheal and flare in histamine test by the main H1 antihistamines commercialized in Brazil |
title_full |
Suppression of wheal and flare in histamine test by the main H1 antihistamines commercialized in Brazil |
title_fullStr |
Suppression of wheal and flare in histamine test by the main H1 antihistamines commercialized in Brazil |
title_full_unstemmed |
Suppression of wheal and flare in histamine test by the main H1 antihistamines commercialized in Brazil |
title_sort |
Suppression of wheal and flare in histamine test by the main H1 antihistamines commercialized in Brazil |
author |
Maciel-Guerra, Helena [UNESP] |
author_facet |
Maciel-Guerra, Helena [UNESP] Jorge, Marília Formentini Scotton [UNESP] Carrijo, Ana Cláudia Nazareno dos Anjos [UNESP] Miot, Hélio Amante [UNESP] Penha, Mariana Álvares [UNESP] Libório, Ricardo da Silva [UNESP] Parise-Fortes, Maria Rita [UNESP] |
author_role |
author |
author2 |
Jorge, Marília Formentini Scotton [UNESP] Carrijo, Ana Cláudia Nazareno dos Anjos [UNESP] Miot, Hélio Amante [UNESP] Penha, Mariana Álvares [UNESP] Libório, Ricardo da Silva [UNESP] Parise-Fortes, Maria Rita [UNESP] |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (Unesp) |
dc.contributor.author.fl_str_mv |
Maciel-Guerra, Helena [UNESP] Jorge, Marília Formentini Scotton [UNESP] Carrijo, Ana Cláudia Nazareno dos Anjos [UNESP] Miot, Hélio Amante [UNESP] Penha, Mariana Álvares [UNESP] Libório, Ricardo da Silva [UNESP] Parise-Fortes, Maria Rita [UNESP] |
dc.subject.por.fl_str_mv |
Angioedema Histamine antagonists Histamine H1 antagonists Histamine H2 antagonists Urticaria |
topic |
Angioedema Histamine antagonists Histamine H1 antagonists Histamine H2 antagonists Urticaria |
description |
Background: Several dermatoses are mediated by histamine, such as urticaria, angioedema, and papular urticaria. There are no Brazilian studies comparing the potency of antihistamines. Objectives: To evaluate the tolerability and efficacy of the main commercial brand and generic H1 antihistamines, regarding the suppression of the wheal and flare to the histamine test. Methods: A quasi-experimental, open study with 10 healthy adults submitted to the histamine test on the ventral aspect of the forearms. After 20 minutes, wheal and flares were measured. The tests were performed after two hours of intake of dexchlorpheniramine, hydroxyzine, levocetirizine, fexofenadine, cetirizine, loratadine, ebastine, desloratadine, epinastine and rupatadine, as well as generics of loratadine, cetirizine and fexofenadine. Results: All antihistamines presented a reduction in the wheal compared to the control (p <0.02), as well as in the flare, except for rupatadine (p = 0.70). In the internal comparison, cetirizine, fexofenadine, epinastine, levocetirizine, dexchlorpheniramine and hydroxyzine were the most potent, with no difference between them (p > 0.1). As for halo, cetirizine, epinastine, hydroxyzine and fexofenadine were the most potent, with no difference between them (p > 0.1). The most common adverse effect was drowsiness, which was more prevalent among first-generation drugs (p < 0.01). Generic loratadine, fexofenadine and cetirizine halos were higher than their controls (p <0.03). Study limitations: A single-center study evaluating only aspects related to histamine. Conclusions: Brazilian commercial antihistamines presented different profiles of inhibition of wheal and flares in the histamine test, as well as adverse effects. Generic loratadine, fexofenadine and cetirizine presented larger flares than brand drugs. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-12-11T17:19:49Z 2018-12-11T17:19:49Z 2018-03-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1590/abd1806-4841.20186807 Anais Brasileiros de Dermatologia, v. 93, n. 2, p. 233-237, 2018. 1806-4841 0365-0596 http://hdl.handle.net/11449/176257 10.1590/abd1806-4841.20186807 S0365-05962018000200233 2-s2.0-85046400733 S0365-05962018000200233.pdf |
url |
http://dx.doi.org/10.1590/abd1806-4841.20186807 http://hdl.handle.net/11449/176257 |
identifier_str_mv |
Anais Brasileiros de Dermatologia, v. 93, n. 2, p. 233-237, 2018. 1806-4841 0365-0596 10.1590/abd1806-4841.20186807 S0365-05962018000200233 2-s2.0-85046400733 S0365-05962018000200233.pdf |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Anais Brasileiros de Dermatologia 0,520 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
233-237 application/pdf |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808128114647105536 |